
strateg option co could drive share upward
myl weaker expect result revenu adj ep
lower revenu ep forecast
certainli face number issu
us gener segment call morn call
howev think board decis begin strateg review could
creat valuat floor share estim
ep estim ev ebitda multipl basi current trade
discount teva teva sell pt
work
morgantown
manufactur facil think remedi plan restructur
eventu lead greater effici benefit co
road call manag highlight still expect
potenti approv gener advair year end fda
decis come possibl octob
updat guidanc call mid-teen declin
american segment revenu ep
 remain track plan
pay back debt within next month reduc debt
leverag ratio year end
co gain fda approv biosimilar
rate neulasta pegfilgrastim leukocyt growth factor
month think visibl biosimilar pipelin improv
believ biosimilar product opportun
partner biocon bio rate momenta
valuat maintain buy rate pt arriv
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
myl weaker expect result revenu adj ep lower revenu
ep forecast certainli face number issu
us gener segment call morn call howev think board decis
begin strateg review could creat valuat floor share estim ep
estim ev ebitda multipl basi current trade discount teva teva sell
 incom statement financi project cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
